The discovery of cancer can help revive non-toxic treatment

The discovery of cancer can help revive non-toxic treatment

by

Researchers at the University of Virginia have published a new study that could revive one-time promising treatments that could help fight solid cancer tumors, the university announced Monday. The research successfully set out why the immunotherapy treatments targeted at ovarian, colon and triple negative breast. cancer, pass laboratory tests but fail human trials. Lead researcher Jogender Tushir-Singh, of the UVA School Medicine’s Department of Biochemistry and Molecular Genetics, says the new findings could help resume human trials after new success in laboratory models. So far, researchers and protein engineers around the world, including our research team, have focused on supercharging and superactivating tumor cell death receptors that target antibodies in the fight against cancer, “Tushir-Singh said. Here at UVA, we have taken a comprehensive approach to harnessing the power of the immune system to create double-specific and potentially clinically effective oncological treatments for solid tumors. “

“Our findings also have significant potential to further improve the clinical efficacy of the currently approved PD-L1 antibodies in solid tumors, especially those approved for lethal triple negative breast cancer,” Tushir-Singh added. Scientists first developed an approach. which selectively uses antibodies to name the surface of cancer cells, called death receptor-5 (DR5). The treatment has been successful in clinical trials in the past, which effectively reduced the tumor size in animal trials. When the treatment reached human clinical trials, ‘however, these antibodies did not consistently improve patient survival.’ Tushir-Singh and his team found that the ‘anti-DR5 antibody approaches unintentionally activated biological processes that suppress the body’s immune response’. “the university explained in a statement that the cancer cells could bypass treatment and grow further.

The research shares findings that could restore the effectiveness of treatment by combating the biological process, which has so far been successful in shrinking tumors and improving survival in laboratory mice. “We want to see these strategies in clinical trials, which we strongly believe have great potential in solid tumors,” said Tushir-Singh. ‘Our findings are extraordinary: together with the translation impact, our work explains, after more than 60 years of research in the field, why most approaches focus on apoptosis [cell death] in clinical trials did not perform well and eventually developed resistance to therapies. ”

Source